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Background: Biliverdin IXα is produced when heme undergoes reductive ring cleavage at the α-methene bridge
catalyzed by heme oxygenase. It is subsequently reduced by biliverdin reductase to bilirubin IXα which is a potent
endogenous antioxidant. Biliverdin IXα, through interaction with biliverdin reductase, also initiates signaling
pathways leading to anti-inflammatory responses and suppression of cellular pro-inflammatory events. The use of
biliverdin IXα as a cytoprotective therapeutic has been suggested, but its clinical development and use is currently
limited by insufficient quantity, uncertain purity, and derivation from mammalian materials. To address these
limitations, methods to produce, recover and purify biliverdin IXα from bacterial cultures of Escherichia coli were
investigated and developed.
Results: Recombinant E. coli strains BL21(HO1) and BL21(mHO1) expressing cyanobacterial heme oxygenase gene
ho1 and a sequence modified version (mho1) optimized for E. coli expression, respectively, were constructed and
shown to produce biliverdin IXα in batch and fed-batch bioreactor cultures. Strain BL21(mHO1) produced roughly
twice the amount of biliverdin IXα than did strain BL21(HO1). Lactose either alone or in combination with glycerol
supported consistent biliverdin IXα production by strain BL21(mHO1) (up to an average of 23. 5mg L-1 culture) in
fed-batch mode and production by strain BL21 (HO1) in batch-mode was scalable to 100L bioreactor culture
volumes. Synthesis of the modified ho1 gene protein product was determined, and identity of the enzyme reaction
product as biliverdin IXα was confirmed by spectroscopic and chromatographic analyses and its ability to serve as a
substrate for human biliverdin reductase A.
Conclusions: Methods for the scalable production, recovery, and purification of biliverdin IXα by E. coli were
developed based on expression of a cyanobacterial ho1 gene. The purity of the produced biliverdin IXα and its
ability to serve as substrate for human biliverdin reductase A suggest its potential as a clinically useful therapeutic.
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BioreactorBackground
Biliverdin is a linear tetrapyrrole produced by ring clea-
vage of heme catalyzed by the enzyme heme oxygenase
(HO) (E.C.C.1.14.99.3) [1]. In animals, heme cleavage by
HO occurs selectively at the α−methene bridge to ge-
nerate the most physiologically relevant biliverdin IXα
isomer. Hence, the term “biliverdin” typically refers
specifically to biliverdin IXα, and this usage is applied* Correspondence: jon.takemoto@usu.edu
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reproduction in any medium, provided the orthroughout in this paper. Biliverdin is best known as a
degradative intermediate associated with erythrocyte
and hemoglobin turnover. It is subsequently reduced via
NADPH biliverdin reductase (E.C.C. 1.3.1.24) to bilirubin
IXα that in turn is consecutively bound to serum albu-
min and glucuronic acid for excretion in bile. The overall
process serves to eliminate heme - which is toxic when
accumulated.
Bilirubin IXα is also known to associate with cell
membranes where it quenches the propagation of react-
ive oxygen species (ROS) [2,3] conferring protection to
membrane lipids and proteins against oxidative damage.
Thus, an additional function of biliverdin is to serve as
the immediate source of bilirubin IXα that in turn actstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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din is oxidatively regenerated after bilirubin IXα reacts
with ROS [4-7]. Though bilirubin IXα is an effective
ROS quencher, biliverdin administered at tissue injury/
inflammatory sites appears as effective a cytoprotectant
as bilirubin IXα [8-13]. Biliverdin‘s effectiveness has been
attributed to its hydrophilicity and efficient conversion
to bilirubin IXα [1]. In addition, biliverdin interaction
with biliverdin reductase signals the downstream pro-
duction of anti-inflammatory cytokine interferon-10 [14]
and the nitrosylation-dependent inhibition of pro-
inflammatory TLR4 expression [15]. Thus, biliverdin,
acting together with biliverdin reductase, is increasingly
recognized as a potential anti-inflammatory therapeutic
agent [3,16-18]. Examples of its cytoprotective effects in
animal models include those for ischemia/reperfusion
following liver [19] and small bowel [10] transplants,
vascular injury [20], endotoxic shock [21], vascular in-
timal hyperplasia [9], and nephropathy [8]. In addition,
biliverdin has been reported to inhibit in vitro replica-
tion of hepatitis C [22] and other viruses [23,24] and to
reverse parameters of type 2 diabetes in mice [25]. The
growing list of potential clinical applications for biliver-
din suggests a future need for high-quality preparations
in ample quantity.
Biliverdin is also produced by microbes and plants
[26-30]. In cyanobacteria, red algae, and plants, it serves
primarily (and perhaps solely) as precursor to photo-
sensitive linear tetrapyrroles such as phycocyanobilin
and phycoerythrobilin [31]. These in turn serve as
chromophores for cyanobacterial and red algal light-
harvesting phycobiliprotein complexes and the light-
sensing receptor phytochrome [27,32]. In these organisms,
biliverdin IXα is the predominant isomer produced via
HO enzymes with sequence homologies to mammalian
HO1 [28,33,34].
To meet the projected pharmaceutical demand for
biliverdin, high yield and low cost methods that provide
the IXα isomer in high purity and preferably from non-
mammalian sources are needed. Currently, commercial
biliverdin is predominantly derived by chemical oxida-
tion of bilirubin [35]. The source bilirubin (that occurs
in conjugated form) is extracted from mammalian bile
under acidic conditions that generate isomers (e.g. IIIα
and XIIIα isoforms) and consequently lead to biliverdin
preparations of unsuitable purity (e.g. as low as 38% bili-
verdin IXα [36]). Reported non-mammalian synthesis of
biliverdin include Escherichia coli cultures expressing
HO1 from rat [37,38] and cyanobacteria [39] and yeast
cultures supplemented with hemoglobin [40]. In these
reports, the amounts of biliverdin produced are not
documented or appear low. Biliverdin extracted from
salmon bile is reported [41], but the potential for scal-
able production is not discussed.Here, we report the use of E. coli to synthesize bili-
verdin and describe procedures for the scalable produc-
tion of the IXα isomer. This was achieved by sequence
optimization of the cyanobacterial ho1 gene for
enhanced expression in E. coli and development of
growth culture parameters that promote biliverdin
production.
Methods
E. coli strains and vectors
One ShotW TOP10 Chemically Competent E. coli (Life
Technologies, Carlsbad, CA, USA) was used to construct
the recombinant plasmids. BL21 StarTM (DE3) Chemically
Competent E. coli (Life Technologies, Carlsbad, CA,
USA) was used for transformation and protein expres-
sion. Expression vector constructions were done with
pET101/D-TOPOW (Life Technologies, Carlsbad, CA,
USA) and pJexpress 401 (DNA2.0, Menlo Park, CA,
USA).
Construction of expression vectors
pET101-HO
The heme oxygenase gene (ho1) of Synechocystis
PCC6803 was amplified by PCR of Biobrick gene part
BBaI15008 (Registry of Standard Parts, The BioBricks
Foundation, http://biobricks.org/) using forward primer
5’-CACC ATGAGTGTC AACTTAGCTTC-3’ and re-
verse primer 5’-CTAGCCTTCGGAGGTGGCGA-3’ and
cloned into pET101/D-TOPOW to generate plasmid vec-
tor pET101-HO1 (Figure 1A) with expression under
T7lac promoter control according to instructions pro-
vided by Life Technologies (Carlsbad, CA) (TOPOW
Cloning Reaction Method). The ho1 gene sequence was
verified by DNA sequencing. The vector pET101-HO1
was transformed into BL21 StarTM (DE3) Chemically
Competent E. coli to give E. coli strain BL21(HO1).
pJexpress401-mHO1
The ho1 gene sequence was codon optimized for expres-
sion in E. coli using DNA2.0 Algorithms (DNA2.0, Inc.,
Menlo Park, CA, USA) (Figure 2). The coding sequence
for hexahistidine was incorporated at the 5’ end to provide
a 6X His tag at the N-terminus of the synthesized protein.
The E.coli codon optimized gene (mho1) was synthesized
and inserted into plasmid vector pJexpress401 by DNA2.0
Inc. (Menlo Park, CA, USA). The resulting vector,
pJexpress401-mHO1 (Figure 1B), was transformed into
BL21 StarTM (DE3) Chemically Competent E. coli to give
E. coli strain BL21(mHO1).
Testing carbon sources for biliverdin production
Several carbon sources at different concentrations and in
combination were examined for capabilities to support
Figure 1 Gene maps of expression vectors pET101-HO1 (A) and
pJexpress401-mHO1 (B). ho1 gene expression in (A) is controlled
by T7lac promoter which consists of a strong bacteriophage T7
promoter and a downstream 25 bp lac operator in pET101. For
mho1 expression (B), an “IP-free” T5 promoter sequence was used
with the lac operator placed downstream of the T5 promoter in
the vector pJexpress 401.
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(HO1) and BL21(mHO1). Cultures were grown in
125mL capacity Erlenmeyer flasks on a New Brunswick
G76 rotary incubator shaker (30°C, 200 rpm) in 50mL
Luria-Bertani (LB) medium [42] with various single car-
bon sources that included sucrose (1% wt vol-1), manni-
tol (0.1, 1, 2, 5, 10 and 20% wt vol-1), sorbitol (1, 5,10
and 20% wt vol-1), lactose (1, 2.5, 5 and 10% wt vol-1),
succinate (2% (wt vol-1), malate (2%) or combinations of
carbon sources that included mannitol (1% wt vol-1) +
glucose (1% wt vol-1), sucrose (1% wt vol-1) + glucose
(1% wt vol-1), mannitol (1% wt vol-1) + sorbitol (2.5% wt
vol-1), or mannitol (5% wt vol-1) + sorbitol (5% wt vol-1).
Ampicillin or kanamycin (100μg mL-1) was used for se-
lection, and isopropyl-β−thiogalactopyranoside (IPTG)
(0.5mM) was added (at cell density with absorbance
(1 cm) (A600) of ~0.5) as inducer except when lactose
was the carbon source. Growth was monitored at A600
and the culture color was recorded when stationary
phase growth was achieved (24 to 48h). Biliverdin levels
were estimated by absorbance spectroscopy using a
mM extinction coefficient of 25 at 650nm (1cm light
path length) using a SpectraMax Plus384 Absorbance
Microplate Reader (Molecular Devices, Sunnyvale,
CA, USA).Biliverdin production using bioreactor batch cultures
For bioreactor inocula, E. coli strains BL21(HO1) and
BL21(mHO1) were grown in 50mL of LB medium plus
100μg mL-1 ampicillin or kanamycin, respectively, in
250mL capacity Erlenmeyer flasks with rotary shaking
(225 rpm) at 37o C to an A600 of 2 to 6 with LB medium
as a blank control. Inoculum cultures (80mL) were added
to 2L of modified New Brunswick Scientific (NBS)
medium [43] with 2% (wt vol-1) lactose in place of glu-
cose or modified ZY medium [44] composed of per
L: 2g lactose, 2.2g glucose, 16g glycerol, 15g N-Z-AmineTM
A or 10g Hy Express System II (SheffieldTM Bio-Science,
Norwich, NY), 10g yeast extract (FisherScientific), 1mL
2M MgSO4, 50mL of 20X NP solution (66g (NH4)2SO4,
136g KH2PO4, 142g Na2HPO4 in 1L twice-distilled
H2O), and 1mL 1000X trace elements solution (50 mL
of 1% HCl, 0.675g FeCl3, 0.15g CaCl2, 0.1g MnCl2,
0.015g ZnSO4, 0.023g CoCl2, 0.015g CuCl2, 0.023g NiCl2,
0.025g Na2MoO4, 0.007g H3BO3 in distilled water to a
final volume of 250mL). Separately, 20X NP solution and
2M MgSO4 were autoclaved and 1000X trace elements
solution was filter-sterilized, and the solutions were
added to complete the preparation of modified ZY
growth medium. Batch culture growth was conducted
in a New Brunswick Scientific (Endfield, CT, USA) Bio-
flo 310 Controller bioreactor using BioCommand soft-
ware with a 5L capacity vessel. A dissolved O2 level of
40% was cascade controlled and monitored by gassing
with O2 (0 - 50%) and air (0.75 - 4 SLPM). No antifoam
was used. For fed-batch experiments, a 200mL solution
of 10% (wt vol-1) glycerol, 2% (wt vol-1) lactose, and with
or without 5% (wt vol-1) peptone was continuously fed
(8mL h-1 L-1) during exponential growth beginning 4h
after inoculation. Cell culture absorbance (A600) was
approximately 10 at 4h and 29 at 11h after culture in-
oculation. Growth was terminated approximately 25h
after inoculation. Green material (containing biliverdin)
accumulated in foam above the culture liquid surface
and on the inner surfaces of the bioreactor vessel and in
the foam over-flow material that was siphoned into a
flask outside the vessel. The pigmented material was
collected using methanol or distilled water as necessary
and the pH of the final suspension was lowered to 4.3
or 4.5, respectively, to promote biliverdin precipitation.
The recovered material was centrifuged at 7477xg for 6
min, and the sedimented blue-green material was sus-
pended in methanol. Non-sedimenting biliverdin in
aqueous fractions was recovered by readjusting the pH
to 4.3 followed by re-centrifugaton and suspension of
the green pellet in methanol. The pooled methanolic
solutions were placed on a rotating shaker (225 rpm) at
room temperature for 15min. The solution was centri-
fuged at 4500xg for 4min to remove particles from so-
lution. Fresh methanol was added to the pellet, and the
Figure 2 Gene sequence of ho1 of cyanobacterium Synechocystis PCC6803 (red), E. coli expression optimized mho1 gene sequence
(blue) and the corresponding translated ho1 protein sequence (black).
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with distilled methanol until the A650 of a 1:10 dilution
of the supernatant fluid is less than 0.5. The amounts of
biliverdin recovered were quantitated by HPLC with
comparisons to known amounts of authentic biliverdin
IXα (Frontier Scientific, Inc., Logan, Utah).
Larger (100L) batch cultures of E. coli strain BL21
(HO1) were grown at 37°C with NBS medium contain-
ing 2% (wt vol-1) lactose in a B. Braun UE-100D bio-
reactor (B. Braun Melsungen AG, Germany). Fed-batch
mode was not used. E. coli strain BL21(HO1) inoculum
cultures (4L) were grown overnight at 37°C in LB
medium in Bioflo310 bioreactors. Inoculum cultures (4L)
were added to 100L growth medium and growth was
terminated 24h following inoculation. Biliverdin wascollected, extracted and purified as described above for
the 2L bioreactor batch cultures.HO identification and activity
HO cell extraction
Aliquots (48 to 400mL) of bioreactor batch cultures of
E. coli strain BL21(mHO1) were collected at 2, 5, 10, 15
and 2h after inoculation, centrifuged (4500xg, 5min),
and the supernatant liquid discarded. The sedimented
cell pellets were stored at −20°C. The cells were
extracted, and proteins were recovered from Ni-NTA
columns using the QIAexpressW Ni-NTA fast Start Kit
(QIAGEN, Valencia, CA, USA) according to procedures
described in the kit manual.
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Twenty μL of each protein solution from Ni-NTA
column purification were added to 20μLof SDS-PAGE
sample buffer (Bio-Rad, Hercules, CA, USA), heated
for 10min with boiling water, and centrifuged briefly.
Supernatant liquid aliquots (30μL) were loaded into wells
of Bio-Rad Criterion Precast Gels and electrophoresed in
a Bio-Rad Criterion precast Gel System. The gel was
stained using Bio-safeTM Coomassie G-250 (Bio-Rad,
Hercules, CA, USA). Precision Plus Protein Prestained
Standards (Bio-Rad Laboratories, Hercules, CA, USA)
was used for estimation of protein molecular size.
Identification
Ni-NTA column purified protein samples were reduced
and alkylated with iodoacetamide. The resulting peptides
were concentrated on a ZipTip micropurification co-
lumn and eluted onto an anchorchip target for analysis
on a Bruker Autoflex III MALDI TOF/TOF instrument
(performed by Alphalyse, Inc., Palo Alto, CA, 94306).
The peptide mixture was analyzed in positive reflector
mode for accurate peptide mass determination. MALDI
MS/MS analyses were performed on 8 separate peptides
for partial peptide sequencing. The MS and MS/MS
spectra were combined and analyzed using Mascot soft-
ware and NCBI protein databases.
HO activity
Harvested E. coli strains BL21(mHO1) and BL21 StarTM
(DE3) cells were washed and suspended in assay buffer
(50 mM Tris–HCl, pH 7.7, 10% wt vol-1 glycerol) and
1mM EDTA, and disrupted three times using a French
press cell operated at 18,000 psi. The lysate was centri-
fuged at 15,000xg, and the supernatant fraction was
used for HO activity assays similar to published proce-
dures [28,45]. The enzyme reaction mixture (500μL)
contained assay buffer, 40μM methemalbumin, 2.5mM
Tiron, 20μg mL-1 ferredoxin, 0.02 units of ferredoxin
reductase (Sigma-Aldrich, St. Louis, USA), and cell
lysate (0.128mg protein). The reaction was initiated with
the addition of 0.2mg of NADPH and the mixture was
incubated at 37°C for 20min in the dark. The mixture
was then extracted and esterified [46] and biliverdin
dimethyl ester was quantitated by HPLC using a
Beckman C18 Ultrasphere column (4.6 mm x 15 cm),




Ammonium acetate (0.1M, 1.5L) was mixed with
biliverdin in buffered methanol (60% 0.1 M ammonium
acetate/40% methanol, vol vol-1, 1L) and the mixture wasloaded onto a glass column (4.0mm x 300mm) packed
with C18 silica beads (125Å pore, 55-105μM diameter,
Waters, Manchester, UK). The column was precondi-
tioned by sequential elution with 200mL of methanol
and 200mL of buffered methanol. After loading the
sample, the column was washed with 100mL buffered
methanol solution. Biliverdin was eluted with 30% 0.1M
ammonium acetate/70% MeOH (vol vol-1) solution and
collected as material in a green band. To 25mL of eluted
biliverdin material was gradually added 400mL of
1mM HCl with stirring. The solution was kept at −20°C
for 1h and then centrifuged for 15min at 11325xg at
4°C. The supernatant fluid was removed, the biliverdin
pellet was washed and suspended in 20mL H2O in a
50-mL capacity plastic centrifuge tube and centrifuged
for 15min at 4500xg at 4°C. The supernatant fluid was
discarded, the biliverdin pellet was frozen at −80°C and
then freeze-dried using a FreeZone Plus Freeze Dry
System (Labconco, Kansas City, MO USA).
Biliverdin characterization
Absorbance spectra
Absorbance spectra (300 and 800nm) were obtained
using a SpectraMax Plus384 Absorbance Microplate
Reader (Molecular Devices, Sunnyvale, CA, USA).
HPLC analysis
Biliverdin samples (20μL were subjected to HPLC using
a SymmetryW C18 column (4.6mm x 75 mm) and a gra-
dient of solvent A: 99.9% H20, 0.1% trifluoroacetic acid
and solvent B: 99.9% methanol and 0.1% trifluoroacetic
acid. The elution gradient program was: 100% solvent A,
1min; 0-60% solvent B, 1min; 60-100% solvent B, 8 min,
0-100% solvent A, 1min; 100% solvent A, 4 min with a
flow rate of 1mL min-1 using a Waters Alliance HPLC
(Waters, Manchester, UK).
Proton NMR analysis
NMR data was collected on a JEOL Eclipse 400MhZ
NMR (JEOL, Peabody, MA, USA). Biliverdin samples
were dissolved in DMSO-d6 (Cambridge Isotope Labs,
Andover, MA USA).
LC-MS analysis
Biliverdin samples were analyzed on a NanoACQUITY
UPLC (Waters, Manchester, UK) and a Q-Tof Primer
tandem mass spectrometer (Waters, Manchester, UK).
Samples (3μL) were introduced into a SymmetryW C18
trapping column (180μM x 20mm) with NanoACQUITY
Sample Manager (Waters, Manchester, UK) washed with
99% solvent A and 1% solvent B for 3min at 15μL min-1.
Solvent A was 99.9% H20, 0.1% formic acid and solvent
B was 99.9% acetonitrile and 0.1% formic acid. Chemi-
cals were eluted from the trapping column over a
Table 1 Biliverdin production by E. coli (HO1) and E. coli
(mHO-1) growing in LB medium supplemented with
various carbon sources
E.coli Strain Carbon Source Conc. % IPTG a Pigment b
BL21(HO1) D-glucose 1 + pale green
2 + pale green
5 + yellow green
sucrose 1 + brown
D-mannitol 1 + pale green
2 + pale green
5 + green
D-sorbitol 1 + yellow green
5 + yellow green
10 + yellow green
lactose 1 - pale green
2.5 - green
5 - yellow green
10 - yellow green
D-mannitol, D-glucose 1,1 + pale green
sucrose, D-glucose 1,1 + pale green
D-mannitol, D-sorbitol 2.5, 2.5 + green
D-mannitol, D-sorbitol 2, 5 + green
D-mannitol, D-sorbitol 5, 5 + green
lactose, D-glucose 2, 2 - green
succinate 5 + pale green
malate 5 + pale green
citrate 5 + pale green
L- glutamate 5 + pale green
L- glutamate 5 + yellow green
BL21(mHO1) D-glucose 1 + green
D-mannitol 5 + green
lactose 2.5 - green
lactose, D-glucose 2, 2 - green
aIsopropyl-β-thiogalactoside (IPTG), 0.5 mM added (+), or not added (−).
b Biliverdin concentrations were 2 to 4mg L-1 (green), <2 to >0.2 mg L-1
(pale green) and <0.2mg L-1 (yellow green and brown).
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B, 0.1min; 4-98% solvent B, 19.9min; 98-85% solvent B,
2min; 85% solvent B, and 10min, 85-1% solvent B, 8min)
at a flow rate of 0.8μL min-1. MS scan time was 1.0 sec.
NADPH biliverdin reductase activity
The enzymatic conversion of biliverdin to bilirubin was
measured using the Biliverdin Reductase Assay Kit
(Sigma-Aldrich, St. Louis, MO, USA). One mg of biliver-
din producd by strain E. coli strain BL21(mHO1) was
dissolved in 2mL methanol, and 0.2mL was mixed with
1mL of the kit assay buffer. The kit-supplied recombinant
human biliverdin reductase A enzyme was suspended in
800μL water, and 160μL of the enzyme suspension was
added to 480μL of assay buffer. Biliverdin-containing kit
assay buffer (50μL), biliverdin reductase solution (200μL),
and NADPH solution (0.24mg mL-1 NADPH in assay buf-
fer, 750μL) were combined and the absorbance spectrum
between 300-800nm was measured at 0, 15, 30, 45, 60, 90,
145, 240 and 360min using a SpectraMax Plus384 Absorb-
ance Microplate Reader (Molecular Devices, Sunnyvale,
CA, USA).
Results and discussion
Effect of carbon source on biliverdin production
Several potential carbon sources, alone and in combi-
nation, were examined for their abilities to support bili-
verdin production by E. coli strains BL21(HO1) and
BL21(mHO1) growing in LB medium (Table 1). Lactose
at 2 and 2.5% (wt vol-1) alone or in combination with D-
glucose yielded green cultures containing 2 to 4mg L-1
biliverdin without IPTG addition. E. coli strain BL21
(HO1) cultures grown with D-mannitol (alone or in
combination with glucose or sorbitol) also yielded green
cultures whereas other carbon compounds and combi-
nations (Table 1) yielded brown or yellow-green and pale
green cultures containing <0.2 and <2mg L-1 biliverdin,
respectively. Similarly, E. coli strain BL21(mHO1) pro-
duced enhanced amounts of biliverdin with lactose alone
or in combination with D-glucose. These results show
that certain carbohydrates and particularly lactose (2 to
2.5% wt vol-1), alone or in combination with D-glucose,
and D-mannitol (2 to 5% wt vol-1) support higher levels
of biliverdin production by E. coli strains BL21(HO1)
and BL21(mHO1) growing in LB medium as compared
to other carbon sources. With lactose, the addition of
IPTG was not required for enhanced biliverdin produc-
tion offering a practical and economic advantage for
large-scale, commercial production of biliverdin.
Bioreactor batch culture production of biliverdin
Based on observations that lactose enhanced biliverdin
production, modified ZY medium containing 2% wt vol-1
lactose was used to grow E. coli strains BL21(HO1) andBL21(mHO1) in 2 L volumes in a New Brunswick Scien-
tific Bioflo 310 Controller bioreactor. Consistent biliver-
din production was achieved with 40% dissolved O2,
agitation between 280 and 500 rpm, and continuous
feeding of lactose (2% wt vol-1) and glycerol (10% wt vol-1)
in fed-batch mode initiated 4h after culture inoculation
(exponential growth phase). Biliverdin was visible as and
collected in green material that accumulated in the foam
above the culture liquid surface (Figure 3). Biliverdin was
identified and quantitated by HPLC analyses of the col-
lected material. E. coli strains BL21(HO1) and E. coli
BL21(mHO1) produced between 2.5 and 5mg (n=3,
Figure 3 Biliverdin production from E. coli strain BL21 (mHO1)
growing in modified ZY medium in a New Brunswick Bioflo 310
bioreactor. Biliverdin is subsequently extracted from the green-
colored material that accumulates above the culture surface.
Figure 4 SDS-PAGE of eluted solutions from Ni-NTA columns of
cell extracts derived from bioreactor cultures of E. coli strain
BL21 (mHO1) harvested at various times during growth on ZY
medium. Gel lanes are: mixture of protein molecular size standards
(a), and cell extracts from cultures harvested at 2h, (b), 5h (c),
10h (d), 15h (e) and 25 h (f) after culture inoculation. Expression of
29Kd ho1 is evident (right arrow) and not visible when derived
from cells grown without lactose or glucose + IPTG (not shown).
Gel positions of 37Kd and 25Kd protein markers are indicated by
arrows (left side).
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6.4mg) of biliverdin, respectively, per L of culture. There-
fore, E. coli strain BL21(mHO1) produced nearly twice
the amount of biliverdin than E.coli strain BL21(HO1) in
the bioreactor cultures growing in modified ZY medium
in fed-batch mode with lactose and glycerol. In contrast,
the two strains produced approximately the same
amounts of biliverdin when grown in LB medium with
lactose (2.5% wt vol -1) in small shaker flasks (Table 1).
When peptone was included in the fed-batch medium
(together with lactose and glycerol), E. coli strain BL21
(mHO1) bioreactor cultures produced between18.4 to
25.3mg L-1 (n=11, average of 23.8 mg L-1) of biliverdin.
E.coli strain BL21(HO1) produced between 3 and 3.9mg
L-1 (n=9, average of 3.3 mgL-1) in modified NBS medium
in batch mode.
Biliverdin production was also achieved in a 100L bio-
reactor (Braun UE-100D) batch mode cultures of E. coli
strain BL21(HO1) grown in NBS medium containing 2%
(wt vol-1) lactose. Biliverdin yields ranging between 200
to 311mg (n=5, average 212) were achieved. This rate of
production was similar to that achieved by E. coli strain
BL21(HO1) in the 2L bioreactor (Bioflo 310) batch modecultures (average rate: 3.3mg L-1) indicating that biliver-
din production by E. coli strain BL21(HO1) is scalable to
larger volumes and quantities.
HO expression and activity
When grown in 2L bioreactor cultures, E. coli strain
BL21(mHO1) cells contained Ni-NTA recoverable pro-
teins with molecular size ~29 Kd and detectable initially
between 2 to 5h after inoculation and then until growth
was terminated (25h) (Figure 4). The proteins were
equivalent in size to ho1 of Synechocystis PCC6803 with
a 6x-His tag (i.e. 28.7 Kd) and the gel excised protein
showed sequence similarity to the cyanobacterial ho1
(31% sequence coverage, Mascot protein score =146).
Extracts of E. coli strain BL21(mHO1) cells harvested at
25h of bioreactor growth had HO activities of 80 pmol
hr-1 mg protein-1 whereas extracts from E. coli strain
BL21 StarTM (DE3) cells showed no or barely detectable
activities (<5 pmol hr-1 mg protein-1). These results
confirmed that E. coli strain BL21(mHO1) synthesized
an HO enzyme when grown under conditions that
allowed accumulation of green pigment determined to
be biliverdin (see below).
Identification of biliverdin IXα
The identity of the biliverdin extracted from E. coli
strain BL21(mHO1) cultures as biliverdin IXα was indi-
cated by comparisons to authentic biliverdin IXα using
Figure 5 Spectral and chromatographic analyses of biliverdin produced by bioreactor cultures of E. coli BL21 (mHO1). (A) Absorbance
spectra of biliverdin produced by E. coli BL21 (mHO1) (red) and commercial biliverdin IXα derived from an animal source (blue). (B) HPLC
chromatograms of biliverdin produced by E. coli BL21 (mHO1) (top) and commercial biliverdin IXα derived from an animal source (bottom).
(C) One dimensional proton NMR (400 Mhz) spectrum of E. coli BL21 (mHO1)-produced biliverdin in DMSO-d6. 1H NMR (400 MHz, DMSO) signal
assignments are: 12.32 (s; 2H); 12.1(s; 1H); 12.01 (s; 1H); 10.78 (s; 1H); 10.67 (s; 1H); 7.58 (s; 1H); 6.91 (t, J= 15.6 Hz; 1H); 6.69 (t, J= 15.2 Hz; 1H); 6.32
(d, J= 12.2 Hz; 3H); 5.82 (d, J=10.8 Hz; 1H); 5.56 (d, J= 11.2 Hz; 1H); 5.78 (s; 1H); 3.05 (m; 4H); 3.43 (m; 4H); 2.18 (s; 3H); 2.27 (s; 3H); 2.15 (s; 3H); 2.01
(s; 3H). The spectrum is similar to biliverdin IXα derived from animal sources [36].
Figure 6 Absorbance spectra at various times during bilirubin
formation from E. coli BL21 (mHO1)-produced biliverdin
catalyzed by human recombinant biliverdin reductase A.
NADPH-dependent reduction was monitored spectrophotometrically
for 6h. The arrows indicate the direction of absorbance change over
time during the reaction.
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copy (Figure 5) and mass spectroscopy (mass 582.2).
The degree of purity was >98% based on HPLC profiles
(biliverdin IXα retention time of 6.6 min, Figure 5B).
E. coli produced biliverdin as substrate for biliverdin
reductase A
Purified biliverdin produced by E. coli BL21(mHO1) was
reduced to bilirubin IXα by recombinant human biliver-
din reductase A and NADPH (Figure 6). Since human
biliverdin reductase A specifically uses biliverdin IXα as
substrate [1,35], this result confirms the identity of the
E. coli BL21(mHO1) produced biliverdin as the IXα iso-
mer. It also suggests that the produced biliverdin has
therapeutic potential because of its substrate interaction
with the human enzyme and its facile conversion to bili-
rubin IXα.
Conclusions
Methods for the scalable production of biliverdin by E.
coli cultures were developed. Production is enhanced
Chen et al. BMC Biotechnology 2012, 12:89 Page 9 of 10
http://www.biomedcentral.com/1472-6750/12/89with the use of an altered version of a cyanobacterial
ho1 gene that is sequence-optimized for E. coli expres-
sion. The produced biliverdin is solely the physiologically
relevant IXα isomer and is easily obtained at a high de-
gree of purity (>98%). Its purity and ability to serve as
substrate for human NADPH biliverdin reductase A sug-
gest its potential as a clinically useful therapeutic for in-
flammatory diseases and conditions. When commercially
produced for therapeutic applications, the biliverdin IXα
preparations will undoubtedly require screening for and
elimination of endotoxin contaminants that are a conse-
quence and limitation of industrial scale production by
E. coli cultures.
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